A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
TransCon TLR7/8 Agonist is an investigational drug being developed for treatment of locally
advanced or metastatic solid tumors. This Phase 1/2 study will evaluate TransCon TLR7/8
Agonist as monotherapy or in combination with pembrolizumab in dose escalation and dose
expansion. Participants will receive intratumoral (IT) injection of TransCon TLR7/8 Agonist
every cycle. The primary objectives are to evaluate safety and tolerability, and define the
Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TransCon TLR7/8 Agonist
alone or in combination with pembrolizumab.